1. Home
  2. MSEX vs ESPR Comparison

MSEX vs ESPR Comparison

Compare MSEX & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Middlesex Water Company

MSEX

Middlesex Water Company

HOLD

Current Price

$57.66

Market Cap

984.5M

Sector

Utilities

ML Signal

HOLD

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.16

Market Cap

816.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSEX
ESPR
Founded
1897
2008
Country
United States
United States
Employees
395
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
984.5M
816.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
MSEX
ESPR
Price
$57.66
$3.16
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$61.33
$8.75
AVG Volume (30 Days)
153.9K
9.7M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
2.77%
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
$10.60
N/A
Revenue Next Year
$10.94
$12.81
P/E Ratio
$22.68
N/A
Revenue Growth
N/A
21.31
52 Week Low
$44.94
$1.10
52 Week High
$62.18
$4.18

Technical Indicators

Market Signals
Indicator
MSEX
ESPR
Relative Strength Index (RSI) 73.53 64.86
Support Level $49.91 $3.13
Resistance Level $62.18 $3.18
Average True Range (ATR) 1.20 0.02
MACD 0.47 -0.01
Stochastic Oscillator 93.28 75.00

Price Performance

Historical Comparison
MSEX
ESPR

About MSEX Middlesex Water Company

Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: